Description
PGD3 is produced by the metabolism of EPA via the COX pathway.{1144} It is equipotent to PGD2 in decreasing systemic blood pressure in rats and in decreasing intraocular pressure in rabbits.{1139,1138,1225} However, it is 3-5 times more potent than PGD2 in the inhibition of ADP-induced human platelet aggregation.{1139}
Formal name: 9α,15S-dihydroxy-11-oxo-prosta-5Z,13E,17Z-trien-1-oic acid
Synonyms: PGD3
Molecular weight: 350.5
CAS: 71902-47-1
Purity: ≥98%
Formulation: A solution in methyl acetate
Product Type|Biochemicals|Lipids|Prostaglandins||Research Area|Cardiovascular System|Blood|Coagulation & Hemostasis||Research Area|Cardiovascular System|Cardiovascular Diseases|Hypertension||Research Area|Lipid Biochemistry|Cyclooxygenase Pathway||Research Area|Neuroscience|Ophthalmology